Anti-Cancer Drugs最新文献_第2页

Growth differentiation factor-11 inhibits the progression of acute myeloid leukemia and increases chemosensitivity by inhibiting cathepsin S. 生长分化因子-11通过抑制组织蛋白酶S抑制急性髓系白血病的进展并增加化疗敏感性。

IF 2 4区医学

Anti-Cancer Drugs Pub Date : 2026-10-01 Epub Date: 2026-06-09 DOI: 10.1097/CAD.0000000000001832

Jie Luo, Yun Xu, Lina Zhang, Lan Ding

{"title":"Growth differentiation factor-11 inhibits the progression of acute myeloid leukemia and increases chemosensitivity by inhibiting cathepsin S.","authors":"Jie Luo, Yun Xu, Lina Zhang, Lan Ding","doi":"10.1097/CAD.0000000000001832","DOIUrl":"10.1097/CAD.0000000000001832","url":null,"abstract":"Growth differentiation factor-11 (GDF11) is an important member of the transforming growth factor-β superfamily and plays an important role in tumor progression. However, its role and prognostic value in acute myeloid leukemia (AML) have not been reported. We overexpressed GDF11 to investigate the effect of GDF11 on the behavior of AML cells. The effect of GDF11 on chemotherapy sensitivity was investigated in HL60 cells treated with 10 μM daunorubicin (DNR). Cell viability was detected using the cell counting kit-8 assay. Western blot was performed to analyze the expression levels of target proteins. GDF11 was associated with poor overall survival of AML patients. The proliferation of HL60 cells was inhibited by the transfection of pcDNA3.1-GDF11. GDF11 overexpression upregulated the expression of caspase3-p17 and Bax, while downregulating the Bcl-2 level. Importantly, the decreased cell proliferation and induced apoptosis by DNR were enhanced by GDF11 overexpression. Cathepsin S (CTSS) expression was inhibited by GDF11 in HL60 cells. The overexpression of CTSS attenuated the enhancement of GDF11 on chemotherapy sensitivity. In addition, CTSS activated the extracellular signal-regulated kinase 1 and 2 signaling pathway and inhibited endoplasmic reticulum stress in AML cells. In conclusion, GDF11 inhibited the growth and increased chemosensitivity through inhibiting CTSS expression in AML cells, providing potential therapeutic targets for AML treatment.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":"545-553"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148262833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response of undifferentiated and dedifferentiated endometrial cancer to pembrolizumab: a case report. 未分化和去分化子宫内膜癌对派姆单抗的反应：1例报告。

IF 2 4区医学

Anti-Cancer Drugs Pub Date : 2026-10-01 Epub Date: 2026-04-21 DOI: 10.1097/CAD.0000000000001824

Peter G Rose, Johanna Kelley, Aaron Petty, Robert Soslow

{"title":"Response of undifferentiated and dedifferentiated endometrial cancer to pembrolizumab: a case report.","authors":"Peter G Rose, Johanna Kelley, Aaron Petty, Robert Soslow","doi":"10.1097/CAD.0000000000001824","DOIUrl":"10.1097/CAD.0000000000001824","url":null,"abstract":"To report our experience with pembrolizumab in undifferentiated and dedifferentiated endometrial cancer. We performed an institutional review board-approved, retrospective study of computerized pharmacy records to identify all patients with undifferentiated and dedifferentiated endometrial carcinomas treated with pembrolizumab. Eleven patients who received pembrolizumab were identified with the following stages: International Federation of Gynecology and Obstetrics stages IC (1), IIC (2), IIIB (2), IIIC2 (2), and IVB (4). One hundred and forty cycles of pembrolizumab were administered. Ten of the 11 patients were mismatch repair (MMR)-deficient. Eight of the patients received pembrolizumab in combination with chemotherapy. Three partial and two complete responses were seen. Both complete responses were seen when pembrolizumab was given with chemotherapy. Four patients were treated in the adjuvant setting with pembrolizumab had no measurable disease and were not evaluable for response but remain disease-free. Two treatment-emergent adverse effects were noted: colitis and hepatitis. Because of the very high rate of MMR deficiency in undifferentiated and dedifferentiated endometrial carcinomas, incorporation of immunotherapy to chemotherapy should strongly be considered in patients with this histologic type in advanced and early-stage disease.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":"573-577"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147809719","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

D430-2307 inhibits breast cancer cell growth by dual induction of apoptosis and G0/G1 arrest via phosphatidylinositol 3-kinase/protein kinase B signaling. D430-2307通过磷脂酰肌醇3-激酶/蛋白激酶B信号通路双诱导凋亡和G0/G1阻滞抑制乳腺癌细胞生长。

IF 2 4区医学

Anti-Cancer Drugs Pub Date : 2026-10-01 Epub Date: 2026-03-04 DOI: 10.1097/CAD.0000000000001817

Jingge Xu, Shuling Ni, Yi Yang, Deqiao Sheng, Yayun Liu

{"title":"D430-2307 inhibits breast cancer cell growth by dual induction of apoptosis and G0/G1 arrest via phosphatidylinositol 3-kinase/protein kinase B signaling.","authors":"Jingge Xu, Shuling Ni, Yi Yang, Deqiao Sheng, Yayun Liu","doi":"10.1097/CAD.0000000000001817","DOIUrl":"10.1097/CAD.0000000000001817","url":null,"abstract":"D430-2307 is a novel small-molecule compound identified through virtual screening of the Chemdiv database that markedly inhibited the proliferation of both MCF-7 and MDA-MB-231 breast cancer cells. In the present study, the anticancer activity and underlying molecular mechanisms of D430-2307 were investigated. Thiazolyl blue, colony formation, wound healing, and transwell assays were performed to assess the effects of D430-2307 on breast cancer cell proliferation, migration, and invasion. To elucidate the underlying mechanisms, flow cytometry, Western blotting, and fluorescence staining were performed to analyze cell-cycle distribution, apoptosis, and intracellular reactive oxygen species (ROS) levels. In addition, network pharmacology, transcriptomics, and bioinformatics analyses were integrated to identify core targets and associated pathways, while molecular docking was performed to verify target-ligand interactions. The results demonstrated that D430-2307 significantly inhibited breast cancer cell proliferation, migration and invasion, induced G 0 /G 1 cell cycle arrest, downregulated CDK4/6 expression, and promoted apoptosis through modulation of the Bax/Bcl-2 ratio and activation of caspase-3/7 signaling. Furthermore, D430-2307 suppressed the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signaling pathway via elevation of intracellular ROS levels. These findings suggest that D430-2307 exerts antitumor effects through ROS-mediated suppression of PI3K/AKT signaling, G 0 /G 1 cell cycle arrest, and apoptosis induction, providing a foundation for the development of novel anti-breast cancer therapeutics.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":"554-569"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human Epidermal Growth Factor Receptor-2 positive metastatic salivary duct carcinoma with remarkable response to targeted therapy: a case report and therapeutic implications. 人表皮生长因子受体-2阳性转移性涎腺管癌对靶向治疗的显著反应：一例报告和治疗意义。

IF 2 4区医学

Anti-Cancer Drugs Pub Date : 2026-10-01 Epub Date: 2026-01-22 DOI: 10.1097/CAD.0000000000001814

Clara Rodrigo Juan, Carla Climent Vicente, Francisco Xavier Avilés Jurado, Noemí Bartolomé Cerdà, Joan Lop Gros, Manuel Mazariegos Rubi

引用次数: 0

3-Aminoisoquinolines inhibit selectively phosphodiesterase 4B in KRAS-mutated colorectal cancer cell lines in-vitro and in-vivo. 3-氨基异喹啉在体外和体内抑制kras突变的结直肠癌细胞系选择性磷酸二酯酶4B

IF 2 4区医学

Anti-Cancer Drugs Pub Date : 2026-10-01 Epub Date: 2026-09-09 DOI: 10.1097/CAD.0000000000001819

Gennady B Lapa, Toshiyuki Tsunoda, Natalia I Moiseeva

{"title":"3-Aminoisoquinolines inhibit selectively phosphodiesterase 4B in KRAS-mutated colorectal cancer cell lines in-vitro and in-vivo.","authors":"Gennady B Lapa, Toshiyuki Tsunoda, Natalia I Moiseeva","doi":"10.1097/CAD.0000000000001819","DOIUrl":"10.1097/CAD.0000000000001819","url":null,"abstract":"Phosphodiesterase 4B (PDE4B), an isoform of cyclic nucleotide phosphodiesterases, is integrated into cell membranes and hydrolyzes cyclic AMP in specific cellular compartments. Overexpression of PDE4B has been observed in hematological and gastrointestinal tumors harboring KRAS mutations, leading to the disruption of cell cycle regulation. Utilizing molecular docking, we identified 3-aminoisoquinolines as potential selective PDE4B inhibitors. Phenotypic screening on HKe3-KRAS cell lines confirmed that PDE4B is a selective target for these novel 3-aminoisoquinolines. We employed molecular docking and calculated ligand efficiency as predictive tools for methylthiazoltetrazolium assay activity to reduce the combinatorial library size. Six active compounds (047, 048, 086, 089, 091, and 099) were screened. Active compounds 047, 048, 086, 089, and 091 demonstrated selectivity toward HKe3-mtKRAS over wild-type cells. This 'synthetic lethality-like' approach was effective in predicting the anticancer properties of these compounds in KRAS-mutated cell lines. NCI-DTP 60 cell lines assays confirmed the activities of 047, 048, and 089. Compound 089 showed strong cytotoxicity against HCT-116 cells inhibitory concentration (IC 50 ) = 1.6 μM, growth inhibition (GI 50 ) = 0.53 μM, and an inhibitory concentration (IC 50 ) against PDE4B = 2.5 μM. In addition, 089 exhibited good tolerability in a nude mouse HCT-116 xenograft model, but it was less effective at a dose of 40 mg/kg compared with Apremilast at a dose of 30 mg/kg in 8-s day's assay. While 089 had lower in-vivo efficacy than apremilast, its novel 3-aminoisoquinoline scaffold and high tolerability make it a superior candidate for further optimization.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":"528-535"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147618359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A global perspective in anti-cancer drugs. 抗癌药物的全球视野。

IF 2 4区医学

Anti-Cancer Drugs Pub Date : 2026-10-01 Epub Date: 2026-09-09 DOI: 10.1097/CAD.0000000000001843

Sergio Huerta

引用次数: 0

Remarkable efficacy of ivonescimab-based second-line therapy in advanced lung adenocarcinoma resistant to chemoimmunotherapy: a case report. 依维单抗二线治疗化疗免疫耐药晚期肺腺癌疗效显著1例

IF 2 4区医学

Anti-Cancer Drugs Pub Date : 2026-10-01 Epub Date: 2026-09-09 DOI: 10.1097/CAD.0000000000001825

Xuan Wang, Kunning Yang, Ping Yin

{"title":"Remarkable efficacy of ivonescimab-based second-line therapy in advanced lung adenocarcinoma resistant to chemoimmunotherapy: a case report.","authors":"Xuan Wang, Kunning Yang, Ping Yin","doi":"10.1097/CAD.0000000000001825","DOIUrl":"10.1097/CAD.0000000000001825","url":null,"abstract":"PD-1/PD-L1 inhibitors combined with chemotherapy are the current standard first-line treatment for advanced lung adenocarcinoma (LUAD). However, chemotherapy typically becomes the main therapeutic approach for subsequent treatment once the development of resistance to this initial chemoimmunotherapy, and there are limited effective treatment options available. This case report describes a 41-year-old male patient with stage IVA LUAD (PD-L1 tumor proportion score: 5%, next-generation sequencing: no mutation) who achieved a partial response (PR) with first-line camrelizumab plus pemetrexed and carboplatin, but later experienced disease progression. Upon switching to second-line therapy with ivonescimab (an anti-PD-1/vascular endothelial growth factor-A bispecific antibody) combined with docetaxel, the patient achieved a significant clinical and radiographic response, again evaluated as PR, which was sustained over 12 treatment cycles. Up to now, the progression-free survival (PFS) is more than 12 months, which is significantly longer than the 9-month PFS achieved by the first-line treatment. The regimen was well-tolerated, with only grade 1 adverse events. This case highlights the potential of ivonescimab-based therapy as an effective and manageable second-line option for patients with advanced LUAD who have progressed on prior immune checkpoint inhibitor therapy, even with low PD-L1 expression.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":"570-572"},"PeriodicalIF":2.0,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147809796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathologic complete response after first-line tislelizumab, cetuximab, and dabrafenib in microsatellite-stable BRAF V600E-mutant metastatic colorectal cancer: a case report. 一线替利单抗、西妥昔单抗和达非尼治疗微卫星稳定BRAF v600e突变转移性结直肠癌后的病理完全缓解：1例报告

IF 2 4区医学

Anti-Cancer Drugs Pub Date : 2026-09-30 DOI: 10.1097/CAD.0000000000001846

Rong Li, Yanping Lin, Jiangyan Guo, Junyi Qian, Mingjin Wu, Ya Zhang, Liyao Xiao, Rui Li, Xuan Zhang

{"title":"Pathologic complete response after first-line tislelizumab, cetuximab, and dabrafenib in microsatellite-stable BRAF V600E-mutant metastatic colorectal cancer: a case report.","authors":"Rong Li, Yanping Lin, Jiangyan Guo, Junyi Qian, Mingjin Wu, Ya Zhang, Liyao Xiao, Rui Li, Xuan Zhang","doi":"10.1097/CAD.0000000000001846","DOIUrl":"https://doi.org/10.1097/CAD.0000000000001846","url":null,"abstract":"BRAF V600E-mutant metastatic colorectal cancer (mCRC) is characterized by aggressive disease behavior and limited responsiveness to conventional systemic therapy. Although BRAF/EGFR-targeted therapies have improved clinical outcomes, durable complete remission remains uncommon, particularly in microsatellite-stable (MSS) disease. We report the case of a 26-year-old woman with MSS, BRAF V600E-mutant sigmoid colon adenocarcinoma and synchronous liver and omental metastases (cT4aN2M1c, stage IVC). Pretreatment biopsy demonstrated high programmed death-ligand 1 (PD-L1) expression (combined positive score = 20) and a high density of intratumoral CD8+ T cells (350 cells/mm2). Because the patient declined cytotoxic chemotherapy, first-line treatment consisted of tislelizumab combined with cetuximab and dabrafenib. After approximately 4 months of systemic therapy, radiological assessment showed a partial response, accompanied by normalization of serum marker levels, enabling conversion surgery. Histopathological examination confirmed a pathological complete response in the primary tumor and all resected metastatic lesions. A personalized tumor-informed circulating tumor DNA assay performed 3 months after surgery was negative. At the latest follow-up (35 months after treatment initiation), the patient remained free of clinical and radiological evidence of disease recurrence. This case highlights the possibility that selected patients with MSS, BRAF V600E-mutant mCRC may achieve durable remission with combined programmed cell death protein 1 blockade and dual-targeted therapy. The observed association between high intratumoral CD8+ T-cell infiltration, elevated PD-L1 expression, and favorable treatment response should be considered hypothesis-generating and requires validation in prospective biomarker-driven studies.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2026-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149102802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical ethics in oncology. 肿瘤学临床伦理学。

IF 2 4区医学

Anti-Cancer Drugs Pub Date : 2026-09-01 Epub Date: 2026-08-05 DOI: 10.1097/CAD.0000000000001837

Sergio Huerta

引用次数: 0

The good, the bad, and the manageable: real-world outcomes with CDK4/6 inhibitors. 好的，坏的，可控制的：CDK4/6抑制剂的现实结果。

IF 2 4区医学

Anti-Cancer Drugs Pub Date : 2026-09-01 Epub Date: 2026-01-21 DOI: 10.1097/CAD.0000000000001810

Alexandra Paulet, Silvia Mancini, Martina Catalano, Kristian Shtembari, Claudia De Angelis, Roberto Petrioli, Daniele Generali, Giandomenico Roviello

{"title":"The good, the bad, and the manageable: real-world outcomes with CDK4/6 inhibitors.","authors":"Alexandra Paulet, Silvia Mancini, Martina Catalano, Kristian Shtembari, Claudia De Angelis, Roberto Petrioli, Daniele Generali, Giandomenico Roviello","doi":"10.1097/CAD.0000000000001810","DOIUrl":"10.1097/CAD.0000000000001810","url":null,"abstract":"Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy represent the standard of care for hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC). While clinical trials established their efficacy, real-world evidence on safety, dose adjustments, and outcomes remains limited. We conducted a prospective observational study including patients with HR+/HER2- mBC treated with palbociclib, ribociclib, or abemaciclib across three oncology units between 2019 and 2024. Data on adverse events, dose modifications, progression-free survival (PFS), and overall survival (OS) were collected and analyzed. Adverse events were reported in 77.5% of patients. Neutropenia was the most frequent adverse event with palbociclib and ribociclib, while diarrhea and hepatic toxicity predominated with abemaciclib. Pulmonary toxicity occurred in 19.1% of abemaciclib-treated patients, often in those previously irradiated. Median PFS and OS were 26.4 and 31.1 months, respectively. The occurrence of grade 3-4 adverse events correlated with improved OS (37.1 vs. 23.0 months, P < 0.001). Dose reductions, required in more than 60% of patients, did not compromise efficacy; instead, they were associated with longer PFS and OS. Conversely, treatment discontinuation predicted worse outcomes. In real-world practice, CDK4/6i toxicities are frequent but manageable. Proactive toxicity management and timely dose adjustments are essential to sustain treatment benefit. Dose reductions may even improve outcomes, underscoring the value of individualized dosing strategies.","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":"512-521"},"PeriodicalIF":2.0,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146058879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0